In a report issued on June 29, David Martin from Bloom Burton maintained a Buy rating on Knight Therapeutics (KHTRF), with a price target of C$8.00. The company’s shares closed last Thursday at $5.35.
According to TipRanks.com, Martin is a 5-star analyst with an average return of 28.8% and a 53.2% success rate. Martin covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, ESSA Pharma, and CRH Medical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Knight Therapeutics with a $6.51 average price target, representing a 21.7% upside. In a report issued on June 26, Mackie Research also maintained a Buy rating on the stock with a C$8.90 price target.
See today’s analyst top recommended stocks >>
Based on Knight Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $45.84 million and GAAP net loss of $1.71 million. In comparison, last year the company earned revenue of $2.96 million and had a net profit of $5.19 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.